{"id":"W2118982164","doi":"10.1056/nejmoa1305133","title":"Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma","year":2013,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3395,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Ipilimumab; Rash; Adverse effect; Melanoma; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Cohort; Cancer; Confidence interval; Surgery; Immunotherapy; Chemotherapy; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}